These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23436264)

  • 1. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
    Wynne C; Harvey V; Schwabe C; Waaka D; McIntyre C; Bittner B
    J Clin Pharmacol; 2013 Feb; 53(2):192-201. PubMed ID: 23436264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer.
    Wynne C; Harvey V; Schwabe C; Waaka D; McIntyre C; Bittner B
    J Clin Pharmacol; 2013 Jan; ():. PubMed ID: 23504807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C
    Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
    Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
    Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
    Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
    J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer.
    Melichar B; Študentová H; Kalábová H; Vitásková D
    Immunotherapy; 2014; 6(7):811-9. PubMed ID: 25290414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
    Beeram M; Krop IE; Burris HA; Girish SR; Yu W; Lu MW; Holden SN; Modi S
    Cancer; 2012 Dec; 118(23):5733-40. PubMed ID: 22648179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
    Launay-Vacher V
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1361-7. PubMed ID: 24057040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer.
    Sanford M
    Target Oncol; 2014 Mar; 9(1):85-94. PubMed ID: 24664187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.
    Baselga J; Carbonell X; Castañeda-Soto NJ; Clemens M; Green M; Harvey V; Morales S; Barton C; Ghahramani P
    J Clin Oncol; 2005 Apr; 23(10):2162-71. PubMed ID: 15800309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen.
    Bittner B; Richter WF; Hourcade-Potelleret F; McIntyre C; Herting F; Zepeda ML; Schmidt J
    Arzneimittelforschung; 2012 Sep; 62(9):401-9. PubMed ID: 22918857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.
    Leyland-Jones B; Colomer R; Trudeau ME; Wardley A; Latreille J; Cameron D; Cubedo R; Al-Sakaff N; Feyereislova A; Catalani O; Fukushima Y; Brewster M; Cortés J
    J Clin Oncol; 2010 Feb; 28(6):960-6. PubMed ID: 20026806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.
    Jackisch C; Kim SB; Semiglazov V; Melichar B; Pivot X; Hillenbach C; Stroyakovskiy D; Lum BL; Elliott R; Weber HA; Ismael G
    Ann Oncol; 2015 Feb; 26(2):320-5. PubMed ID: 25403587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab.
    Prescrire Int; 2015 Apr; 24(159):93. PubMed ID: 25941697
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
    J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
    Leyland-Jones B; Gelmon K; Ayoub JP; Arnold A; Verma S; Dias R; Ghahramani P
    J Clin Oncol; 2003 Nov; 21(21):3965-71. PubMed ID: 14507946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.